Latisse

Latisse is a brand name of bimatoprost topical, approved by the FDA in the following formulation(s):

LATISSE (bimatoprost - solution/drops; topical)

• 
  Manufacturer: ALLERGAN
  
  Approval date: December 24, 2008
  
  Strength(s): 0.03% ^[RLD]

Has a generic version of Latisse been approved?

No. There is currently no therapeutically equivalent version of Latisse available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Latisse. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents
  Patent 6,403,649
  Issued: June 11, 2002
  Inventor(s): David F.; Woodward & Steven W.; Andrews & Robert M.; Burk & Michael E.; Garst
  Assignee(s): Allergan Sales, Inc.
  The present invention provides cydopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cydopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cydopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
  
  Patent expiration dates:
  
  
  • September 21, 2012
    
    ✓ 
    Drug substance
  
  



• 
  Method of enhancing hair growth
  Patent 7,351,404
  Issued: April 1, 2008
  Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
  Assignee(s): Allergan, Inc.
  Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
  
  Patent expiration dates:
  
  
  • May 25, 2024
    
    ✓ 
    Patent use: TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
  
  



• 
  Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
  Patent 7,388,029
  Issued: June 17, 2008
  Inventor(s): DeLong; Mitchell Anthony & McIver; John McMillan & Youngquist; Robert Scott
  Assignee(s): Duke University
  A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
  
  Patent expiration dates:
  
  
  • January 21, 2022
    
    ✓ 
    Patent use: TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
  
  



• 
  Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
  Patent 8,017,655
  Issued: September 13, 2011
  Inventor(s): Woodward; David F. & Andrews; Steven W. & Burk; Robert M. & Garst; Michael E.
  Assignee(s): Allergan, Inc.
  The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular hypotensives, and are particularly suitable for the management of glaucoma. Moreover, the cyclopentane heptanoic, 2-(cycloalkyl or arylalkyl) compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; smooth muscle relaxants with application in gastrointestinal disease, reproduction, fertility, incontinence, shock, etc.
  
  Patent expiration dates:
  
  
  • November 27, 2012
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of enhancing hair growth
  Patent 8,038,988
  Issued: October 18, 2011
  Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
  Assignee(s): Allergan, Inc.
  Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
  
  Patent expiration dates:
  
  
  • August 25, 2023
    
    ✓ 
    Patent use: TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Method of enhancing hair growth
  Patent 8,101,161
  Issued: January 24, 2012
  Inventor(s): Woodward; David F. & VanDenburgh; Amanda M.
  Assignee(s): Allergan, Inc.
  Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.
  
  Patent expiration dates:
  
  
  • May 25, 2024
    
    ✓ 
    Patent use: METHOD OF INCREASING THE NUMBER OF HAIRS
    ✓ 
    Drug product
  
  
  
  • May 25, 2024
    
    ✓ 
    Patent use: METHOD OF STIMULATING HAIR GROWTH
    ✓ 
    Drug product
  
  
  
  • May 25, 2024
    
    ✓ 
    Patent use: METHOD OF INCREASING HAIR GROWTH
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 24, 2011 - NEW PRODUCT
  
  

See also...

• Latisse Consumer Information (Drugs.com)